[go: up one dir, main page]

WO2000061737A3 - Production of attenuated negative stranded RNA virus vaccines - Google Patents

Production of attenuated negative stranded RNA virus vaccines Download PDF

Info

Publication number
WO2000061737A3
WO2000061737A3 PCT/US2000/009695 US0009695W WO0061737A3 WO 2000061737 A3 WO2000061737 A3 WO 2000061737A3 US 0009695 W US0009695 W US 0009695W WO 0061737 A3 WO0061737 A3 WO 0061737A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
recombinant
stranded rna
negative stranded
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/009695
Other languages
French (fr)
Other versions
WO2000061737A2 (en
Inventor
Brian R Murphy
Peter L Collins
Anna P Durbin
Mario H Skiadopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0011159-7A priority Critical patent/BR0011159A/en
Priority to JP2000611661A priority patent/JP4646410B2/en
Priority to AU42315/00A priority patent/AU781238B2/en
Priority to EP00922075A priority patent/EP1171623A2/en
Priority to CA002369817A priority patent/CA2369817A1/en
Priority to IL14579700A priority patent/IL145797A0/en
Priority to MXPA01010392A priority patent/MXPA01010392A/en
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to KR1020017013102A priority patent/KR100760328B1/en
Publication of WO2000061737A2 publication Critical patent/WO2000061737A2/en
Publication of WO2000061737A3 publication Critical patent/WO2000061737A3/en
Anticipated expiration legal-status Critical
Priority to US10/916,827 priority patent/US20050287540A1/en
Priority to AU2005203596A priority patent/AU2005203596B8/en
Priority to US12/136,765 priority patent/US20120064569A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18641—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18661—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Attenuated, recombinant negative stranded RNA viruses suitable for vaccine use are produced from one or more isolated polynucleotide molecules encoding the virus. A recombinant genome or antigenome of the subject virus is modified to encode a mutation within a recombinant protein of the virus at one or more amino acid positions(s) corresponding to a site of an attenuating mutation in a heterologous, mutant negative stranded RNA virus. A similar attenuating mutation as identified in the heterologous negative stranded RNA virus is thus incorporated at a corresponding site within the recombinant virus to confer an attenuated phenotype on the recombinant virus. The attenuating mutation incorporated in the recombinant virus may be identical or conservative in relation to the attenuating mutation identified in the heterologous, mutant virus. By the transfer of mutations into recombinant negative stranded RNA viruses in this manner, candidate vaccine viruses are engineered to elicit a desired immune response against a subject virus in a host susceptible to infection thereby.
PCT/US2000/009695 1995-09-27 2000-04-12 Production of attenuated negative stranded rna virus vaccines Ceased WO2000061737A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL14579700A IL145797A0 (en) 1999-04-13 2000-04-12 Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences
JP2000611661A JP4646410B2 (en) 1999-04-13 2000-04-12 Production of attenuated (-) strand RNA virus vaccines from cloned nucleotide sequences
AU42315/00A AU781238B2 (en) 1999-04-13 2000-04-12 Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
EP00922075A EP1171623A2 (en) 1999-04-13 2000-04-12 Production of attenuated negative stranded rna virus vaccines
CA002369817A CA2369817A1 (en) 1999-04-13 2000-04-12 Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences
MXPA01010392A MXPA01010392A (en) 1999-04-13 2000-04-12 Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences.
KR1020017013102A KR100760328B1 (en) 1999-04-13 2000-04-12 Method for preparing the synthesized negative strand RNA virus vaccine from cloned nucleotide sequences
BR0011159-7A BR0011159A (en) 1999-04-13 2000-04-12 Method for producing attenuated negative strand virus RNA vaccines from cloned nucleotide sequences
US10/916,827 US20050287540A1 (en) 1995-09-27 2004-08-11 Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
AU2005203596A AU2005203596B8 (en) 1999-04-13 2005-08-12 Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
US12/136,765 US20120064569A9 (en) 1995-09-27 2008-06-10 Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12900699P 1999-04-13 1999-04-13
US60/129,006 1999-04-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/887,469 Continuation-In-Part US6923971B2 (en) 1995-09-27 2001-06-22 Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09958292 A-371-Of-International 2002-01-08
US10/916,827 Continuation US20050287540A1 (en) 1995-09-27 2004-08-11 Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences

Publications (2)

Publication Number Publication Date
WO2000061737A2 WO2000061737A2 (en) 2000-10-19
WO2000061737A3 true WO2000061737A3 (en) 2001-08-23

Family

ID=22438049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009695 Ceased WO2000061737A2 (en) 1995-09-27 2000-04-12 Production of attenuated negative stranded rna virus vaccines

Country Status (10)

Country Link
EP (1) EP1171623A2 (en)
JP (1) JP4646410B2 (en)
KR (1) KR100760328B1 (en)
CN (1) CN1347458A (en)
AU (2) AU781238B2 (en)
BR (1) BR0011159A (en)
CA (1) CA2369817A1 (en)
IL (1) IL145797A0 (en)
MX (1) MXPA01010392A (en)
WO (1) WO2000061737A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
EP2112220A3 (en) 1996-07-15 2010-01-06 The Government of the United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
JP2003530073A (en) 1999-07-09 2003-10-14 アメリカ合衆国 Production of an attenuated human-bovine chimeric respiratory syncytial virus vaccine
ATE307606T1 (en) * 2001-10-04 2005-11-15 Ct Voor Onderzoek In Diergenee ATTENUATED MUTANT STRAIN OF NEWCASTLE DISEASE VIRUS FOR IN OVO VACCINATION AND USE THEREOF
US7820181B2 (en) 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP2007524372A (en) 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Recombinant human metapneumovirus and uses thereof
KR100999316B1 (en) 2003-06-09 2010-12-10 와이어쓰 엘엘씨 Improved Method for Recovery of Non-Segmented Negative Chain RNA Virus from CDNA
CN101646768A (en) * 2007-02-07 2010-02-10 生物载体株式会社 Attenuated minus-strand RNA viruses
CA2836977A1 (en) * 2010-06-06 2011-12-15 Benjamin R. Tenoever Recombinant rna viruses and uses thereof
CN103525777B (en) * 2013-07-01 2016-05-18 中国农业科学院兰州兽医研究所 Attenuated vaccine strain with L gene mutation of type VII Newcastle disease virus and preparation method thereof
SG11201913826QA (en) * 2017-07-03 2020-01-30 Bharat Biotech Int Ltd A synthetic polypeptide epitope based vaccine composition
WO2019055768A1 (en) * 2017-09-15 2019-03-21 Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
CN111019910B (en) 2019-11-04 2022-03-15 上海青赛生物科技有限公司 F genotype mumps virus attenuated strain and construction method and application
CN111849927B (en) * 2020-06-28 2022-07-08 浙江大学 Method for efficiently producing recombinant nonsegmented negative-sense RNA virus and recombinant virus
CN116676275B (en) * 2023-03-17 2024-06-07 北京赛尔富森生物科技有限公司 A-genotype chimeric mumps virus strain and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002530A1 (en) * 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US5786199A (en) * 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786199A (en) * 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
WO1998002530A1 (en) * 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOUGLAS R G JR ET AL: "LIVE VICTORIA-75-TS-1E INFLUENZA A VIRUS VACCINES IN ADULT VOLUNTEERS ROLE OF HEM AGGLUTININ IMMUNITY IN PROTECTION AGAINST ILLNESS AND INFECTION CAUSED BY INFLUENZA A VIRUS", INFECTION AND IMMUNITY, vol. 26, no. 1, 1979, pages 274 - 279, XP000991444, ISSN: 0019-9567 *
DURBIN ANNA P ET AL: "Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates.", VIROLOGY, vol. 261, no. 2, pages 319 - 330, XP000098705, ISSN: 0042-6822 *
DURBIN ANNA P ET AL: "Recovery of infectious human parainfluenza virus type 3 from cDNA.", VIROLOGY, vol. 235, no. 2, 1997, pages 323 - 332, XP000986915, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
AU781238B2 (en) 2005-05-12
CA2369817A1 (en) 2000-10-19
IL145797A0 (en) 2002-07-25
AU4231500A (en) 2000-11-14
AU2005203596A1 (en) 2005-09-08
MXPA01010392A (en) 2003-09-15
KR100760328B1 (en) 2007-10-04
JP2002541798A (en) 2002-12-10
KR20020008831A (en) 2002-01-31
JP4646410B2 (en) 2011-03-09
EP1171623A2 (en) 2002-01-16
CN1347458A (en) 2002-05-01
BR0011159A (en) 2002-07-23
WO2000061737A2 (en) 2000-10-19
AU2005203596B2 (en) 2008-09-11
AU2005203596C1 (en) 2009-12-10
AU2005203596B8 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
WO2000061737A3 (en) Production of attenuated negative stranded RNA virus vaccines
MXPA02006888A (en) Recombinant flaviviruses and methods of use thereof.
EP0953648A3 (en) Viral defective vaccine produced by transcomplementing cell line
BR9205771A (en) Recombinant virus vector and process for its manufacture
CA2505942A1 (en) West nile virus vaccine
CA2230033A1 (en) Production of infectious respiratory syncytial virus from cloned nucleotide sequences
RU2011104999A (en) HEMAGGLUTININ AND INFLUENZA VIRUS NEURAMIDASE OPTIONS
CA2334857A1 (en) Interferon inducing genetically engineered attenuated viruses
JP2005523318A5 (en)
WO2003088994A3 (en) Modified vaccinia virus ankara for the vaccination of neonates
RU2003103779A (en) EXPRESSION SYSTEM
DK2295065T3 (en) Modified heat shock protein-antigen peptide complex
MXPA01008966A (en) Nucleic acid respiratory syncytial virus vaccines.
CN106139139A (en) swine fever E2 subunit vaccine and application thereof
CN113293148B (en) Construction of a chimeric measles attenuated strain with H gene replacement
EP1434862A4 (en) Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the cns
CN117143924B (en) Recombinant feline herpesvirus co-expressing feline calicivirus and feline parvovirus antigenic proteins and its live vector vaccine and application
RU2011137404A (en) HEMAGGLUTININ AND INFLUENZA INFLUENZA OPTIONS
JP2012517239A5 (en)
WO2003097673B1 (en) Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide,virus-like particles prepared therefrom and a method for preparing the particles.
WO2004009763A3 (en) Use of vaccinia virus deleted for the e3l gene as a vaccine vector
AU2002212555A1 (en) Yeast derived vaccine against ipnv
WO2000012677A3 (en) Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines
WO2002047720A3 (en) Treatment and prevention of ebv infection and ebv-associated disorders
IE871639L (en) Varicella-zoster virus.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00806224.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2369817

Country of ref document: CA

Ref document number: 2369817

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017013102

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 611661

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010392

Country of ref document: MX

Ref document number: 2000922075

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09958292

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000922075

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642